Dandan Dong, Ph.D., is a Managing Director with a background in academic biomedical science research and translational medicine. She has more than eight years’ experience in healthcare investments in both the United States and China. As a member of Vivo’s cross-border strategy, she has been involved in multiple transactions in both countries and cross-border deals. She was also involved in founding VISEN Pharmaceuticals and currently serves as VISEN’s Chief Business Officer. She is a managing member of Vivo PANDA Fund, Vivo’s early-stage investment vehicle.
She has conducted research in infectious disease and immunology and published her research in multiple peer-reviewed journals, including Infection and Immunity, the Journal of Infectious Disease etc. Dr. Dong holds a Ph.D. in biomedical science from Fudan University and she has completed the Pre-doctoral Fellowship program at New York University School of Medicine.